GlobalData’s patient-based forecast predicts Tecvayli will reach a peak of $2.1bn in sales globally by 2030 in MM.
Patients with newly diagnosed multiple myeloma experienced robust clinical activity when treated with Tecvayli (teclistamab) ...
Johnson & Johnson announces positive Phase II results for Tecvayli in newly diagnosed multiple myeloma, with all patients ...
Janssen-Cilag International NV, a Johnson & Johnson company, today announced new frontline data featuring TECVAYLI®â–¼ (teclistamab) from two investigational studies in patients with newly diagnosed ...
Johnson & Johnson (JNJ) announced new frontline data featuring TECVAYLI (teclistamab-cqyv) from two investigational studies in ...
Johnson & Johnson announced new frontline data featuring TECVAYLI from two investigational studies in patients with newly diagnosed ...
Teclistamab is an off-the-shelf (or ready to use) bispecific antibody. 6 Teclistamab, a subcutaneous injection, redirects T-cells through two cellular targets (BCMA and CD3) to activate the body's ...
Genmab's royalty revenues are expected to exceed $2.5 billion this year and potentially $4 billion at peak. See why I rate ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback